WO2001091733A3 - Combinaison de principes actifs contenant de la montireline et un compose a effet opioide - Google Patents

Combinaison de principes actifs contenant de la montireline et un compose a effet opioide Download PDF

Info

Publication number
WO2001091733A3
WO2001091733A3 PCT/EP2001/005345 EP0105345W WO0191733A3 WO 2001091733 A3 WO2001091733 A3 WO 2001091733A3 EP 0105345 W EP0105345 W EP 0105345W WO 0191733 A3 WO0191733 A3 WO 0191733A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
active substances
montirelin
compound
substances containing
Prior art date
Application number
PCT/EP2001/005345
Other languages
German (de)
English (en)
Other versions
WO2001091733A2 (fr
Inventor
Boris Chizh
Thomas Christoph
Babette-Yvonne Koegel
Achim Schuettler
Wolfgang Strassburger
Original Assignee
Gruenenthal Gmbh
Boris Chizh
Thomas Christoph
Koegel Babette Yvonne
Achim Schuettler
Wolfgang Strassburger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh, Boris Chizh, Thomas Christoph, Koegel Babette Yvonne, Achim Schuettler, Wolfgang Strassburger filed Critical Gruenenthal Gmbh
Priority to AU2001274020A priority Critical patent/AU2001274020A1/en
Publication of WO2001091733A2 publication Critical patent/WO2001091733A2/fr
Publication of WO2001091733A3 publication Critical patent/WO2001091733A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une combinaison de principes actifs contenant de la montiréline et un composé à effet opioïde et/ou respectivement leurs sels physiologiquement tolérables. Elle concerne également des médicaments contenant cette combinaison de principes actifs, des formulations de médicaments contenant ladite combinaison, ainsi que l'utilisation de cette combinaison pour produire un médicament.
PCT/EP2001/005345 2000-05-26 2001-05-10 Combinaison de principes actifs contenant de la montireline et un compose a effet opioide WO2001091733A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001274020A AU2001274020A1 (en) 2000-05-26 2001-05-10 Combination of active substances containing montirelin and compound having an opioid effect

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10025947A DE10025947A1 (de) 2000-05-26 2000-05-26 Wirkstoffkombination enthaltend Montirelin und eine Verbindung mit opioider Wirksamkeit
DE10025947.2 2000-05-26

Publications (2)

Publication Number Publication Date
WO2001091733A2 WO2001091733A2 (fr) 2001-12-06
WO2001091733A3 true WO2001091733A3 (fr) 2002-04-04

Family

ID=7643551

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/005345 WO2001091733A2 (fr) 2000-05-26 2001-05-10 Combinaison de principes actifs contenant de la montireline et un compose a effet opioide

Country Status (5)

Country Link
AR (1) AR029096A1 (fr)
AU (1) AU2001274020A1 (fr)
DE (1) DE10025947A1 (fr)
PE (1) PE20011272A1 (fr)
WO (1) WO2001091733A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
JP6141583B2 (ja) * 2010-02-24 2017-06-07 シマ ラブス インク． 濫用耐性製剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426378A (en) * 1981-04-09 1984-01-17 The United States Of America As Represented By The Secretary Of The Army Thyrotropin releasing hormone in therapy of shock and as a central nervous system stimulant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426378A (en) * 1981-04-09 1984-01-17 The United States Of America As Represented By The Secretary Of The Army Thyrotropin releasing hormone in therapy of shock and as a central nervous system stimulant

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BHARGAVA HEMENDRA N ET AL: "Effect of thyrotropin releasing hormone on U-50,488H-induced pharmacological responses in mice.", BRAIN RESEARCH, vol. 625, no. 1, 1993, pages 120 - 124, XP001029522, ISSN: 0006-8993 *
ITOH YOSHINORI ET AL: "Enhancement of brain noradrenaline and dopamine turnover by thyrotropin-releasing hormone and its analogue NS-3 in mice and rats.", PHARMACOLOGY & TOXICOLOGY, vol. 78, no. 6, 1996, pages 421 - 428, XP001029649, ISSN: 0901-9928 *
UKAI YOJIRO ET AL: "Effects of montirelin hydrate (NS-3), a TRH analog, on the cerebral glucose utilization and high affinity choline uptake in rats.", OYO YAKURI, vol. 51, no. 3, 1996, pages 147 - 153, XP001022252, ISSN: 0300-8533 *
WANG G-L ET AL: "EFFECTS OF THYROTROPIN-RELEASING HORMONE ON ACUTE EXPERIMENTAL TRAUMATIC HEAD INJURY IN CATS", CHINESE MEDICAL JOURNAL (ENGLISH EDITION), vol. 104, no. 11, 1991, pages 939 - 944, XP001022253, ISSN: 0366-6999 *
YAMAMOTO M ET AL: "EFFECTS OF YM-14673 A NEW TRH ANALOGUE ON RESPONSES TO MORPHINE IN RODENTS", ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE, vol. 300, 1989, pages 29 - 36, XP001029545, ISSN: 0003-9780 *
ZHUKOV V N ET AL: "HYPERTHERMIA AND ANTINOCICEPTIVE ACTIVITY OF TRH AND MORPHINE FOLLOWING CENTRAL ADMINISTRATION IN RATS", ACTA PHYSIOLOGICA ET PHARMACOLOGICA BULGARICA, vol. 14, no. 2, 1988, pages 18 - 23, XP001022256, ISSN: 0323-9950 *

Also Published As

Publication number Publication date
DE10025947A1 (de) 2001-11-29
AR029096A1 (es) 2003-06-04
AU2001274020A1 (en) 2001-12-11
PE20011272A1 (es) 2002-01-26
WO2001091733A2 (fr) 2001-12-06

Similar Documents

Publication Publication Date Title
WO2000041681A3 (fr) FORMULATIONS DE MEDICAMENTS CONTENANT UN OPIOIDE ET UN α-AGONISTE
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
EP1246608A4 (fr) Formulations pharmaceutiques pour l'administration de medicaments ayant une faible solubilite aqueuse
IL149186A0 (en) Pharmaceutical compositions providing enhanced drug concentrations
EP0960621A3 (fr) Compositions pharmaceutiques comprenant du sildenafil
WO2007009806A3 (fr) Formulations posologiques solides de medicaments narcotiques presentant une adsorption buccale amelioree
MXPA03007712A (es) Sales farmaceuticas.
AU2001283563A1 (en) Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
AU2002239397A1 (en) Drug formulation having improved oral tolerability
AU2002227910A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
AU2001234114A1 (en) Drugs containing combined active ingredients
WO2002019969A3 (fr) Acide (5-(2-hydroxy-4-chlorobenzoyl) aminovalerique et ses sels, compositions contenant l'acide et ses sels pour acheminer des agents actifs
WO2000078294A3 (fr) Forme galenique orale servant a administrer une combinaison fixe de tramadol et de diclofenac
AU2001228811A1 (en) Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient
WO2002030467A3 (fr) Composition destinee a soigner des plaies, renfermant un compose actif du point de vue therapeutique, du miel notamment
WO2002015959A3 (fr) Composes et compositions permettant de distribuer des agents actifs
PL346764A1 (en) New oral formulation for 5-ht4
AU2001278772A1 (en) Benzoic acid derivatives and drugs containing the same as the active ingredient
AU2001277738A1 (en) Piperidine derivatives and drugs containing these derivatives as the active ingredient
HUP0303636A3 (en) Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
AU2001291731A1 (en) Pharmaceutical, effervescent formulation containing ramipril
HK1045937A1 (en) Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof
WO2001091733A3 (fr) Combinaison de principes actifs contenant de la montireline et un compose a effet opioide
GEP20043377B (en) Pharmaceutical Complex

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP